Sabbagh Ali, Keikhaei Bijan, Joorabian Morteza, Behzad Masumeh Maleki, Momeni Mohammad
Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Blood Cells Mol Dis. 2019 Feb;74:1-4. doi: 10.1016/j.bcmd.2018.09.005. Epub 2018 Sep 20.
Portal vein thrombosis (PVT) has been described as a rare complication after splenectomy. PVT associated risk factors after splenectomy in hematological disorders are poorly recognized. The aim of this study was to assess the prevalence and risk factors of PVT incidence in splenectomized patients.
One hundred twelve splenectomized patients with various hematologic diseases between 2008 and 2018 were enrolled in this study. Diagnosis was confirmed by Doppler ultrasonography (DUSG) and risk factors for PVT were sought based on the comparison of clinical and laboratory features between patients without and with PVT.
PVT was diagnosed in 4 (3.57%) patients in spite of receiving antiplatelet therapy. Patients with PVT were β-thalassemia major (n = 2) and β-thalassemia intermedia (n = 2). β-thalassemia patients had a 3.5 times higher odds for PVT (95% CI: 2.41-5.33). No significant differences between patients with and without PVT in terms of age, gender and laboratory features were found.
According to our data, β-thalassemia, especially intermediate form, may be a risk factor for PVT and it can occur in spite of receiving antiplatelet therapy. Given that β-thalassemia patients are at risk, early PVT detection may be useful for reduction of fatal PVT complication in splenectomized patients.
门静脉血栓形成（PVT）被认为是脾切除术后一种罕见的并发症。血液系统疾病患者脾切除术后PVT相关的危险因素鲜为人知。本研究旨在评估脾切除患者中PVT发生的患病率及危险因素。
本研究纳入了2008年至2018年间112例因各种血液系统疾病接受脾切除术的患者。通过多普勒超声检查（DUSG）确诊，并根据有无PVT患者的临床和实验室特征比较来寻找PVT的危险因素。
尽管接受了抗血小板治疗，仍有4例（3.57%）患者被诊断为PVT。PVT患者为重型β地中海贫血（n = 2）和中间型β地中海贫血（n = 2）。β地中海贫血患者发生PVT的几率高3.5倍（95%CI：2.41 - 5.33）。在年龄、性别和实验室特征方面，有PVT和无PVT的患者之间未发现显著差异。
根据我们的数据，β地中海贫血，尤其是中间型，可能是PVT的一个危险因素，并且即使接受抗血小板治疗也可能发生。鉴于β地中海贫血患者存在风险，早期检测PVT可能有助于降低脾切除患者致命性PVT并发症的发生。
